
Monogram (MGRM) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
0
Gross Profit
0
Operating Income
-3.1M
Net Income
-5.4M
EPS (Diluted)
$-0.16
Balance Sheet Metrics
Total Assets
15.4M
Total Liabilities
3.7M
Shareholders Equity
11.7M
Debt to Equity
0.31
Cash Flow Metrics
Operating Cash Flow
-2.7M
Free Cash Flow
-2.5M
Revenue & Profitability Trend
Monogram Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 0 | 365.0K | 0 | 628.2K | 0 |
Cost of Goods Sold | - | - | 0 | 458.7K | 0 |
Gross Profit | - | - | 0 | 169.6K | 0 |
Gross Margin % | 0.0% | 0.0% | 0.0% | 27.0% | 0.0% |
Operating Expenses | |||||
Research & Development | 8.8M | 10.6M | 5.4M | 5.3M | 4.7M |
Selling, General & Administrative | 6.5M | 7.0M | 5.2M | 5.2M | 2.2M |
Other Operating Expenses | - | - | -256.0K | - | - |
Total Operating Expenses | 15.3M | 17.6M | 10.4M | 10.4M | 6.9M |
Operating Income | -15.3M | -17.3M | -10.4M | -10.3M | -6.9M |
Operating Margin % | 0.0% | -4,731.0% | 0.0% | -1,635.9% | 0.0% |
Non-Operating Items | |||||
Interest Income | 526.0K | 434.3K | 98.1K | 26.1K | 131.5K |
Interest Expense | - | - | - | 21.7K | 54.2K |
Other Non-Operating Income | -1.5M | 3.1M | -3.4M | -1.6M | -2.3M |
Pre-tax Income | -16.3M | -13.7M | -13.7M | -11.8M | -9.1M |
Income Tax | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Net Income | -16.3M | -13.7M | -13.7M | -11.8M | -9.1M |
Net Margin % | 0.0% | -3,765.8% | 0.0% | -1,880.6% | 0.0% |
Key Metrics | |||||
EBITDA | -14.9M | -19.9M | -6.5M | -8.4M | -6.6M |
EPS (Basic) | $-0.46 | $-0.61 | $-0.44 | $-0.38 | $-0.29 |
EPS (Diluted) | $-0.46 | $-0.61 | $-0.44 | $-0.38 | $-0.29 |
Basic Shares Outstanding | 32571470 | 22409222 | 30917015 | 30917015 | 30917015 |
Diluted Shares Outstanding | 32571470 | 22409222 | 30917015 | 30917015 | 30917015 |
Income Statement Trend
Monogram Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 15.7M | 13.6M | 10.5M | 5.5M | 5.6M |
Short-term Investments | - | - | - | - | - |
Accounts Receivable | 0 | 365.0K | 0 | - | - |
Inventory | 288.0K | - | 4.6K | 0 | - |
Other Current Assets | 305.0K | 354.9K | 380.4K | -11.1K | - |
Total Current Assets | 16.3M | 14.6M | 11.3M | 6.5M | 6.4M |
Non-Current Assets | |||||
Property, Plant & Equipment | 1.3M | 1.4M | 1.5M | 939.2K | 934.9K |
Goodwill | 339.0K | 548.8K | 758.8K | 968.8K | 150.0K |
Intangible Assets | - | - | 1.3M | 968.8K | 150.0K |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | - | - | - | - | - |
Total Non-Current Assets | 1.5M | 2.0M | 2.4M | 2.2M | 1.7M |
Total Assets | 17.8M | 16.6M | 13.7M | 8.7M | 8.1M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 1.2M | 2.5M | 663.2K | 449.0K | 182.8K |
Short-term Debt | 138.0K | 128.3K | 118.2K | 92.9K | 57.5K |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | - | - | 7.5M | 4.1M | 2.5M |
Total Current Liabilities | 1.5M | 2.8M | 9.0M | 5.1M | 3.0M |
Non-Current Liabilities | |||||
Long-term Debt | 226.0K | 363.7K | 492.0K | 118.6K | 147.9K |
Deferred Tax Liabilities | - | - | - | - | - |
Other Non-Current Liabilities | 1.5M | - | 1 | 1 | - |
Total Non-Current Liabilities | 1.7M | 363.7K | 492.0K | 118.6K | 147.9K |
Total Liabilities | 3.3M | 3.2M | 9.5M | 5.2M | 3.1M |
Equity | |||||
Common Stock | 35.0K | 31.3K | 9.7K | 9.7K | 9.7K |
Retained Earnings | -68.0M | -51.5M | -37.8M | -24.1M | -12.3M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 14.5M | 13.4M | 4.1M | 3.5M | 5.0M |
Key Metrics | |||||
Total Debt | 364.0K | 492.0K | 610.2K | 211.5K | 205.5K |
Working Capital | 14.7M | 11.8M | 2.2M | 1.4M | 3.4M |
Balance Sheet Composition
Monogram Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -16.3M | -13.7M | -13.7M | -11.8M | -9.1M |
Depreciation & Amortization | 430.0K | 412.3K | 386.7K | 322.0K | 95.7K |
Stock-Based Compensation | 1.2M | 1.6M | 743.3K | 205.6K | 2.2M |
Working Capital Changes | -924.0K | 1.4M | 425.6K | 294.7K | -832.3K |
Operating Cash Flow | -14.1M | -10.2M | -12.1M | -11.0M | -7.6M |
Investing Activities | |||||
Capital Expenditures | -84.0K | -64.9K | -241.2K | -31.1K | -1.2M |
Acquisitions | - | - | - | - | - |
Investment Purchases | - | - | - | - | - |
Investment Sales | - | - | - | - | - |
Investing Cash Flow | -84.0K | -64.9K | -241.2K | -31.1K | -1.2M |
Financing Activities | |||||
Share Repurchases | -200.0K | - | - | - | - |
Dividends Paid | - | - | - | - | - |
Debt Issuance | - | - | - | 0 | 79.0K |
Debt Repayment | - | - | - | 0 | -840.0K |
Financing Cash Flow | 16.1M | 15.5M | 13.6M | 10.1M | 10.0M |
Free Cash Flow | -14.1M | -13.6M | -8.7M | -10.2M | -6.7M |
Net Change in Cash | 1.9M | 5.2M | 1.2M | -900.7K | 1.2M |
Cash Flow Trend
Monogram Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-13.28
Forward P/E
-12.73
Price to Book
25.56
PEG Ratio
-0.29
Profitability Ratios
Profit Margin
0.00%
Operating Margin
0.00%
Return on Equity
-228.82%
Return on Assets
-72.90%
Financial Health
Current Ratio
2.16
Debt to Equity
3.44
Beta
0.69
Per Share Data
EPS (TTM)
$-0.54
Book Value per Share
$0.24
Revenue per Share
$0.00
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
mgrm | 248.7M | -13.28 | 25.56 | -228.82% | 0.00% | 3.44 |
Abbott Laboratories | 234.4B | 16.89 | 4.63 | 30.93% | 32.43% | 26.50 |
Boston Scientific | 144.2B | 57.93 | 6.43 | 11.55% | 13.55% | 53.09 |
Inogen | 235.3M | -5.69 | 1.17 | -13.46% | -7.58% | 9.54 |
TriSalus Life | 232.9M | 0.09 | -7.83 | 128.34% | -86.61% | -1.73 |
CVRx | 227.8M | -3.29 | 3.93 | -92.33% | -95.61% | 87.24 |
Financial data is updated regularly. All figures are in the company's reporting currency.